Recent Updates
Recently added Catalysts

AZD4721

Phase 1

Chronic Obstructive Pulmonary Disease (COPD). | Small molecule | Respiratory |AstraZeneca PLC|Trials Updated: Jun 25, 2015

AZD4721 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2013

AZD4721 target and mechanism

ModalitySmall molecule

Also known as AZD4721 Solution

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedPLACEBO_CONTROLLED
Total Trials1
Total Enrollment84

FDA Designations

No designations recorded

AZD4721 clinical trials

AZD4721 · 1 trial · 1 indication

Phase 1 1
NCT01962935Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED84 Analytics
PHASE1COMPLETED
Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069
Chronic Obstructive Pulmonary Disease (COPD).
NCT0196293584
Unlock trial analytics

Study Endpoints

Primary Endpoints

Description of the safety profile in terms of Adverse events; blood pressure, heart rate and body temperature; electrocardiograms; clinical chemistry; haematology assessments
From Admission day -1 up to Follow up ( Max 12 weeks)

Same for both part A and B

Description of neutrophils in terms of absolute blood neutrophil count ratio [ANC ratio], time of ANCmin,ss [ANCtmin,ss],
Samples taken for part A day -1, Day 1 at predose,1h,2h,6h and 12h postdose, predose day 2,3,4,5,6,7,8,9,10 predose and at 1h,2h,3h,6h,9h,12h,15h,18h,21h,24h,36h,48h post last dose ( given day 10).

Part A AZD4721

Description of neutrophils in terms of minimum ANC during first 24 hours on Day 1 [Part A only, ANCmin,Day 1], time of ANCmin,Day 1 [ANCtmin,Day 1], minimum ANC ratio during first 24 hours on Day 1 [Part A only, ANCmin ratio,Day 1]
Samples taken for Part A Day 1 at predose, 1h,2h,6h12h and 24h postdose.

Part A AZD4721

Descriptions of neutrophils in terms of minimum ANC during the 24 hours following the last morning dose [ANCmin,ss], mean of ANC values during the 24 hours following the last morning dose [ANCmean,ss],
Samples taken for Part A day10 predose and at 1h,2h,3h,6h,9h,12h,15h,18h,21h,24h post dose

Part A AZD4721

Description of neutrophils in terms of minimum ANC ratio during the 24 hours following the last morning dose [ANCmin ratio,ss], and mean of ANC ratio values during the 24 hours following the last morning dose [ANCmean ratio,ss]).
Samples taken for Part A day 10 predose and at 1h,2h,3h,6h,9h,12h,15h,18h,21h,24h post dose

Part A AZD4721

Description of neutrophils in terms of • absolute blood neutrophil count ratio [ANC ratio], time of ANCmin,ss [ANCtmin,ss],
Part B visit 1 day -1, day 1 predose, 12h, day 2 predose, day 3 predose,3h,6h,9h,12h,15h,18h,21h and 24h post dose

Part B AZD5069

Description of neutrophils in terms of • time of ANCmin,Day 1 [ANCtmin,Day 1],
Part B day 1 predose, 12h and 24h postdose

Part B AZD5069

Description of neutrophile in terms of minimum ANC during the 24 hours following the last morning dose [ANCmin,ss], mean of ANC values during the 24 hours following the last morning dose [ANCmean,ss]
Samples taken Part B day 3 predose,3h,6h,9h,12h,15h,18h,21h and 24h post dose

Part B AZD5069

Description of neutrophils in terms of • absolute blood neutrophil count ratio [ANC ratio], time of ANCmin,ss [ANCtmin,ss]
Samples taken for part B day -1, predose day 1,2,4,6,8,10 and at 1h,2h,3h,6h,9h,12h,15h,18h,21h,24h post dose

Part B AZD4721

Description of neutrophils in terms of time of ANCmin,Day 1 [ANCtmin,Day 1],
Samples taken for part B predose day 1

Part B AZD4721

Description of neutrophils in terms of minimum ANC during the 24 hours following the last morning dose [ANCmin,ss], mean of ANC values during the 24 hours following the last morning dose [ANCmean,ss]
Samples taken part B pre dose day 10 and at 1h,2h,3h,6h,9h,12h,15h,18h,21h,24h post dose

Part B AZD4721

Secondary Endpoints

Description of the pharmacokinetic(PK) profile of AZD 4721 in terms of Maximum plasma concentration (Cmax), maximum plasma concentration divided by dose (Cmax/D), time to Cmax (tmax)
Sample taken Day 1 post dose at 0:20, 0:40,1h, 2h,3h,6h,9h,12h,15h,18h,21h and 24h.
Description of the PK profile of AZD 4721 in terms of area under the plasma concentration-time curve during the dosing interval (AUCtau),), lag-time (tlag), ratio of metabolite AUCtau to parent AUCtau (MRAUC)
Sample taken Day 1 post dose at 0:20, 0:40,1h, 2h,3h,6h,9h,12h,15h,18h,21h and 24h.
Description of the PK profile of AZD 4721 in terms of ratio of metabolite Cmax to parent Cmax (MRCmax)
Sample taken Day 1 post dose at 0:20, 0:40,1h, 2h,3h,6h,9h,12h,15h,18h,21h and 24h.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Part A AZD4721EXPERIMENTALPart A of the study, multiple ascending doses of AZD4721 will be administrated once daily for 10 days
PlaceboPLACEBO_COMPARATORPart A of the study, multiple ascending doses of matching Placebo will be administrated once a daily for 14 days
AZD5069, then AZD4721ACTIVE_COMPARATORPart B of the study, subject will participate in two treatment periods (one with AZD5069 administrated for 3 days and the second period with AZD4721 administrated for 14 days) separated by a wash-out period of 6-10 days between the two periods.

Interventions

NameTypeDescription
AZD4721DRUGPart A - multiple ascending dose, daily; Part B - one dose decided after part A, daily
PlaceboDRUGPart A - multiple ascending dose daily
AZD5069DRUGPart B - one dose decided after part A, twice a day
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 50 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * 1.Provision of signed and dated, written informed consent prior to any study specific procedures. * 2.Healthy male and/or female Caucasian (neither Black/African American nor Japanese) volunteers aged 18 to 50 years with suitable veins for cannulation or repeated venipuncture....

Countries:United Kingdom
Unlock Eligibility Criteria

Frequently asked questions about AZD4721

What is AZD4721?

AZD4721 is an investigational small molecule developed by AstraZeneca PLC for Chronic Obstructive Pulmonary Disease (COPD), a respiratory condition. It has been studied in a Phase 1 clinical trial and is not approved for any use. AZD4721 is also referred to as AZD4721 Solution.

What is AZD4721 used for in COPD?

AZD4721 was studied for Chronic Obstructive Pulmonary Disease (COPD), a respiratory condition. It is an investigational small molecule and has not been approved for the treatment of COPD or any other indication. Its only recorded clinical trial has been completed.

Who makes AZD4721?

AZD4721 is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca sponsored the Phase 1 study of AZD4721 in Chronic Obstructive Pulmonary Disease (COPD).

What phase is AZD4721 in?

AZD4721 is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The drug is investigational and has not been approved by the FDA or any other regulatory agency for Chronic Obstructive Pulmonary Disease (COPD) or any other condition.

What clinical trials is AZD4721 in?

AZD4721 has been evaluated in one completed Phase 1 trial, NCT01962935, titled a study to investigate safety, tolerability and effect of multiple dosing with AZD 4721 and/or with AZD 5069. The trial enrolled 84 participants in the United Kingdom, including healthy volunteers, and was placebo controlled and randomized.

Is AZD4721 the same as AZD4721 Solution?

Yes, AZD4721 Solution is another name for AZD4721. Both refer to the same investigational small molecule developed by AstraZeneca PLC for Chronic Obstructive Pulmonary Disease (COPD). Searches for either name point to the same Phase 1 compound.

Explore more on BiopharmaWatch

AstraZeneca PLC (AZN)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ACompanies A to ZEvery biotech and pharma company we track